Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation

Clinical Therapeutics

Volumn 23, Issue 10, 2001, Pages 1720-1731

  Mofsen, Rick ^a,c   Balter, Jordan ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Des Peres Hospital   (United States)

^c Clinical Research Associates   (United States)

Author keywords

Bioequivalence; Clozapine; Clozaril; Relapse

Indexed keywords

CLOZAPINE; GENERIC DRUG;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; MALE; PSYCHOSIS; RELAPSE;

EID: 0035161425     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80139-9     Document Type: Article

References (17)

1. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
2. Clinical effects of a randomized switch of patients from Clozaril to generic clozapine
3. Comparison of the bioequivalence of generic versus branded clozapine
4. A bioequivalence study of brand and generic clozapine in patients with schizophrenia
5. Pharmacodynamics of antipsychotic drugs in schizophrenia
6. 2 receptor increase in PET study of schizophrenia
7. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine
8. Zenith-Goldline clozapine bioequivalence study suggested by FDA
9. Cognitive evaluation of schizophrenic patients conducted during clozapine bioequivalence study
10. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
11. A physician survey on generic drugs and substitution of critical dose medications
12. Clozapine in the back wards